Why the study?
Does rivaroxaban prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Does rivaroxaban prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Rivaroxaban is an effective and safe alternative to warfarin for stroke prevention in patients with non-valvular atrial fibrillation, offering a lower risk of intracranial hemorrhage despite a higher risk of gastrointestinal bleeding.
May support rivaroxaban as alternative in nonvalvular AF; leaves open need for updated real-world comparisons.
Long-term (indefinitely long) use of oral anticoagulants is the most efficient method of medical prevention of cardioembolic complications of atrial fibrillation (AF). This approach is superior to the effectiveness of antiplatelet agents (as monotherapy by acetylsalicylic acid and its combination with clopidogrel). This summary will present the facts that determined ideas about the place of one of the oral anticoagulants of direct action – rivaroxaban – in the prevention of cardioembolic complications in patients with non-valvular atrial fibrillation. We are talking about a randomized, controlled study ROCKET AF, the results of which became the basis for the approval of rivaroxaban for widespread use in non-valcular atrial fibrillation.
No takes yet. Share an insight, caveat, or question.
I. S. Yavelov (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: